RTQ1 Stock Chart & Stats
€0.73
>-€0.01(-0.65%)
At close: 4:00 PM EDT
€0.73
>-€0.01(-0.65%)
Day’s Range― - ―
52-Week Range€0.56 - €1.04
Previous CloseN/A
Volume0.00
Average Volume (3M)1.33K
Market Cap
€358.03M
Enterprise Value€329.93M
Total Cash (Recent Filing)€20.27M
Total Debt (Recent Filing)€19.86M
Price to Earnings (P/E)―
Beta-0.50
Next Earnings
Apr 22, 2027EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.09
Shares Outstanding489,712,860
10 Day Avg. Volume494
30 Day Avg. Volume1,330
Financial Highlights & Ratios
PEG Ratio0.15
Price to Book (P/B)93.68
Price to Sales (P/S)2052.69
P/FCF Ratio-9.35
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)-0.08
Revenue Forecast (FY)€89.57K
Bulls Say, Bears Say
Bulls Say
Differentiated Oncology PlatformThe pre|CISION platform has shown potentially meaningful tumor-delivery advantages in preclinical comparisons, while its FAP focus addresses a target expressed in many solid tumors. If replicated clinically, this differentiation could support adoption, partnering interest, and a broader oncology pipeline.
Clinical Execution And Pipeline ProgressOn-time first-patient dosing demonstrates operational execution, while AVA6000’s defined expansion dose provides a clearer development path. Progress across two programs reduces reliance on a single near-term milestone and supports continued validation of the therapeutic strategy.
Growing Intellectual Property EstateExpanding protection around sustained-release and dual-payload capabilities can help preserve the commercial value of Avacta’s platform as candidates advance. A broader IP estate may strengthen negotiating leverage with partners and create longer-lasting differentiation from competing approaches.
Bears Say
Cash Runway And Financing DependenceThe projected runway is limited relative to the time required for clinical development, and it excludes partnering income. Continued cash consumption means Avacta may need additional financing or a partnership to sustain programs beyond early 2027, creating execution and dilution risk.
Persistent Losses And Cash BurnPersistent losses and negative cash generation show that the current business does not yet fund its development plans internally. Larger recent outflows increase dependence on external capital, while unstable revenue and negative gross profit make a near-term transition to self-sustaining operations uncertain.
Dependence On A Development PartnerMaking pivotal AVA6000 development contingent on a partner places an important clinical and commercial milestone outside the company’s sole control. Delayed partnering could postpone later-stage trials, extend the path to potential revenue, and increase funding pressure on the remaining pipeline.
Avacta Group plc News
RTQ1 FAQ
What was Avacta Group PLC’s price range in the past 12 months?
Avacta Group PLC lowest stock price was €0.56 and its highest was €1.04 in the past 12 months.
What is Avacta Group PLC’s market cap?
Avacta Group PLC’s market cap is €358.03M.
When is Avacta Group PLC’s upcoming earnings report date?
Avacta Group PLC’s upcoming earnings report date is Apr 22, 2027 which is in 175 days.
How were Avacta Group PLC’s earnings last quarter?
Avacta Group PLC released its earnings results on Sep 30, 2026. The company reported -€0.049 earnings per share for the quarter.
Is Avacta Group PLC overvalued?
According to Wall Street analysts Avacta Group PLC’s price is currently Overvalued.
Does Avacta Group PLC pay dividends?
Avacta Group PLC does not currently pay dividends.
What is Avacta Group PLC’s EPS estimate?
Avacta Group PLC’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Avacta Group PLC have?
Avacta Group PLC has 489,712,860 shares outstanding.
What happened to Avacta Group PLC’s price movement after its last earnings report?
Avacta Group PLC reported an EPS of -€0.049 in its last earnings report. Following the earnings report the stock price went down -0.602%.
Which hedge fund is a major shareholder of Avacta Group PLC?
Currently, no hedge funds are holding shares in DE:RTQ1
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Avacta Group plc Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Technicals
SMA
Negative
20 days / 200 days
Momentum
-7.51%
12-Months-Change
Fundamentals
Return on Equity
-1293.07%
Trailing 12-Months
Asset Growth
5.83%
Trailing 12-Months
Learn more about TipRanks Smart Score
Company Description
Avacta Group PLC
Avacta Group Plc operates as a clinical-stage biopharmaceutical company, specializing in the development of cancer therapies and diagnostic solutions. These advancements are driven by its proprietary Affimer and pre|CISION technology platforms, with the company's activities spanning the United Kingdom, North America, South Korea, and broader regions of Asia and Europe. Functioning across distinct Diagnostics and Therapeutics segments, Avacta's diagnostic endeavors include crafting bespoke Affimer proteins for customer products, developing internal diagnostic assays such as the AffiDX SARS-CoV-2 rapid antigen test, and supplying Affimer reagents for integration into third-party offerings. Concurrently, its Therapeutics division is dedicated to pioneering novel cancer immunotherapies through the strategic combination of its proprietary technologies. The company maintains a comprehensive network of collaborations, notably including a research partnership focused on its pre|CISION technology, which utilizes a substrate highly sensitive to cleavage by fibroblast activation protein alpha. Further key alliances encompass a drug development collaboration with LG Chem Life Sciences; a strategic partnership with Tufts University School of Medicine to advance Affimer drug conjugate therapies; a licensing agreement with POINT Biopharma Inc. for the creation of tumor-activated radiopharmaceuticals; and a drug development partnership with AffyXell, aimed at developing engineered mesenchymal stem cells for autoimmune disease treatment. Avacta Group Plc was established in 2003 and is headquartered in Wetherby, United Kingdom.
Technical Analysis
Nuformix Plc
―
PureTech Health
―
Scancell Holdings
―
4basebio UK Societas
―
Arecor Therapeutics PLC
―